LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026PMID: 41633461

View on PubMed DOI: 10.1016/j.cgh.2026.01.024

Semaglutide

Plain Language Summary

Comparative study evaluating LiverPRO (a novel non-invasive steatotic liver disease biomarker panel) against FIB-4 for screening accuracy and health economic impact in terms of false positive reduction and referral cost savings for MASLD management. Positions LiverPRO within the context of emerging pharmacological therapies including resmetirom and semaglutide that require accurate patient identification. Provides evidence for improving MASLD screening efficiency—showing that better non-invasive staging tools could substantially reduce unnecessary referrals and optimize candidate selection for semaglutide MASH therapy.

Abstract

Targeted screening for steatotic liver disease (SLD) is cost-effective and encourages lifestyle changes.The European Association for the Study of the Liver (EASL) recommends screening adults at risk of SLD to enable timely diagnosis and prevention, especially with emerging treatments like resmetirom and semaglutide.EASL guidelines suggest the fibrosis-4 index (FIB-4) as the first-line noninvasive test to identify candidates for secondary care referral with more accurate, resource-intensive assessments like liver stiffness measurements by transient elastography (TE)..

Authors

Thorhauge, Katrine; Lindvig, Katrine; Schnefeld, Helle; Bech, Katrine Tholstrup; Thiele, Maja; Krag, Aleksander